Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies

S Morteza Seyed Jafari,Kristine Heidemeyer,Robert E. Hunger,Pierre A. de Viragh

DOI: https://doi.org/10.3390/jcm13113052

IF: 3.9

2024-05-24

Journal of Clinical Medicine

Abstract:The most common type of alopecia in women is female androgenetic alopecia (FAGA), characterized by progressive hair loss in a patterned distribution. Many oral therapies, including spironolactone (an aldosterone antagonist), androgen receptor blockers (e.g., flutamide/bicalutamide), 5-alpha-reductase inhibitors (e.g., finasteride/dutasteride), and oral contraceptives, target the mechanism of androgen conversion and binding to its respective receptor and therefore could be administered for the treatment of FAGA. Despite significant advances in the oral treatment of FAGA, its management in patients with a history of gynecological malignancies, the most common cancers in women worldwide, may still be a concern. In this review, we focus on the safety of antiandrogens for the treatment of FAGA patients. For this purpose, a targeted literature review was conducted on PubMed, utilizing the relevant search terms. To sum up, spironolactone seems to be safe for the systemic treatment of FAGA, even in high-risk populations. However, a general uncertainty remains regarding the safety of other medications in patients with a history of gynecologic malignancies, and further studies are needed to evaluate their long-term safety in patients with FAGA and risk factors to establish an optimal risk assessment and treatment selection protocol.

medicine, general & internal

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the drug safety of anti - androgen drugs in the treatment of female androgenetic alopecia (FAGA) for patients with a history of gynecological malignancies. Specifically, the paper focuses on whether these drugs will increase the risk of cancer recurrence or other adverse reactions in female patients with a history of gynecological cancer.

### Background of the paper and problem statement

1. **Female androgenetic alopecia (FAGA)**
- FAGA is the most common type of hair loss in women, manifested as gradual and patterned hair thinning.
- Commonly used oral therapies include spironolactone (an aldosterone antagonist), androgen receptor blockers (such as flutamide/bicalutamide), 5 - α - reductase inhibitors (such as finasteride/dutasteride), and oral contraceptives, etc.

2. **Gynecological malignancies**
- Breast cancer and gynecological malignancies are the most common cancer types in women.
- There are concerns about the safety of using anti - androgen drugs in patients with a history of these cancers, especially whether these drugs will increase the risk of cancer recurrence.

3. **Research objectives**
- Through a literature review, evaluate the long - term safety of anti - androgen drugs in the treatment of FAGA for patients with a history of gynecological malignancies.
- Pay special attention to the safety of drugs such as spironolactone, 5 - α - reductase inhibitors (such as finasteride/dutasteride), cyproterone acetate (CPA), flutamide, and bicalutamide.

### Main findings

1. **Spironolactone**
- A large number of studies have shown that the long - term safety of spironolactone in the general population is good.
- In breast cancer survivors, spironolactone does not significantly increase the risk of breast cancer recurrence.
- Therefore, spironolactone may be a relatively safe option for the treatment of FAGA, especially in high - risk groups.

2. **5 - α - reductase inhibitors (finasteride/dutasteride)**
- These drugs are widely used in men, but there is less data in women.
- At present, there is no evidence that these drugs will increase the risk of breast cancer in women, but more controlled trials are needed to evaluate their long - term safety, especially in patients with a history of gynecological cancer.

3. **Cyproterone acetate (CPA)**
- CPA has anti - androgen and some anti - gonadotropin effects and is commonly used to treat hirsutism, acne, and androgenetic alopecia.
- However, long - term use of CPA may be associated with an increased risk of meningioma, so it is not recommended for patients with risk factors for breast cancer or meningioma.

4. **Flutamide and bicalutamide**
- Flutamide is mainly used for the treatment of prostate cancer. Due to its potential hepatotoxicity, it is no longer used for the treatment of FAGA.
- Bicalutamide is a more effective androgen receptor blocker. Recently, studies have shown its potential efficacy in some types of breast cancer.
- These drugs can be considered as second - or third - line options, but more research is still needed to evaluate their safety in high - risk populations.

### Conclusion

The paper summarizes the existing literature and proposes a decision - making algorithm based on existing guidelines and research. It is recommended that when treating FAGA patients with a history of gynecological malignancies, minoxidil should be given priority, followed by spironolactone, and finally 5 - α - reductase inhibitors or potent anti - androgen drugs (such as bicalutamide) should be considered in refractory or severe cases. However, more controlled trials are still needed in the future to evaluate the long - term safety and effectiveness of these treatment regimens.